Terrence L. Fisher

Terrence L. Fisher

*This is an algorithmically generated author record based on publicly available information.

Terrence L. Fisher has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer

    by Michael R. Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae E. Pastore, Crystal L. Mallow, Ernest Smith, Vikas Mishra, Andreas Schröder, Kevin M. Chin, et al.

    Purpose: The CLASSICAL-Lung clinical trial tested the combination of pepinemab, an IgG4 humanized mAb targeting semaphorin 4D, with the PD-L1 inhibitor avelumab to assess the effects of coupling increased T-cell infiltration and reversal of immune suppression via pepinemab with sustained T-cell activation via checkpoint inhibition. Patients and Methods: This phase Ib/II, single-arm study was designed to evaluate the safety, tolerability, and efficacy of pepinemab in combination with avelumab in 62 patients with advanced non–small cell lung cancer (NSCLC), including immunotherapy-naïve (ION) patients and patients whose tumors progressed following anti-PD-1/L1 monotherapy (IOF). The main objectives were to evaluate safety/tolerability, establish a recommended phase 2 dose (RP2D), obtain a preliminary evaluation of antitumor activity, and investigate candidate biomarker activity. Results: The combination was well tolerated with no major safety signals identified. Pepinemab, 10 mg/kg with avelumab, 10 mg/kg, every 2 weeks, was selected as the RP2D. Among 21 evaluable ION patients, 5 patients experienced partial responses (PR), 4 patients evidenced clinical benefit ≥1 year, and the disease control rate (DCR) was 81%. Notably, overall response rate with the combination therapy was higher than previously reported for single-agent avelumab in the PD-L1-negative/low population. Among 29 evaluable IOF patients, the combination resulted in a DCR of 59%, including 2 PR and 7 patients with durable clinical benefit of ≥23 weeks. Biomarker analysis of biopsies demonstrated increased CD8 T-cell density correlating with RECIST response criteria. Conclusions: The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy-resistant and PD-L1-negative/low tumors.


  • Open Access

    Saturation monitoring of VX15/2503, a novel semaphorin 4D‐specific antibody, in clinical trials

    by Terrence L. Fisher, Jennifer Seils, Christine Reilly, Virginia Litwin, Lisa Green, Janelle Salkowitz‐Bokal, Robin Walsh, Sarah Harville, John E. Leonard, Ernest Smith, et al.

    Background: Receptor occupancy, or saturation, assays are often utilized in preclinical and clinical development programs to evaluate the binding of a biologic to a cellular target. These assays provide critical information regarding the dose of drug required to “saturate” the target as well as important pharmacodymamic (PD) data. A flow cytometric method was developed to measure the degree of Semaphorin 4D (SEMA4D; CD100) saturation by VX15/2303, an investigational monoclonal antibody specific for SEMA4D.Methods: The assay detects VX15/2503, a human IgG4 specific for SEMA4D, with an IgG4‐specific monoclonal antibody.Results: Data generated allowed assessment of two related SEMA4D‐specific pharmacodynamic (PD) markers: (1) The measurement of cellular SEMA4D (cSEMA4D) saturation by VX15/2503, and (2) the cell membrane expression levels of cSEMA4D.Conclusions: This assay specifically and reproducibly measured cSEMA4D saturation and expression levels. Evaluation of the SEMA4D‐specific PD markers were critical in determining the clinical saturation threshold of cSEMA4D by VX15/2503. © 2015 he Authors Cytometry Part B: Clinical Cytometry Published by Wiley Periodicals, Inc.


  • Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts).

    by Amita Patnaik, Ramesh K. Ramanathan, Drew Warren Rasco, Glen J. Weiss, Valerie Campello-Iddison, Cynthia Eddington, Terrence L. Fisher, Danielle Mutz, Lisa Blaydorn, Anthony W. Tolcher, et al.

    3052^ Background: Semaphorin 4D (SEMA4D) regulates cellular adhesion, motility and activation of cells of the nervous, vascular and immune systems; it also promotes tumor progression and metastasis. SEMA4D and its receptor plexin B1 are widely expressed in human tumors; the interaction of plexin B1 with MET and ERBB2 leads to SEMA4D-mediated transactivation of these membrane receptor kinases promoting tumor cell migration and invasive growth. The murine progenitor of VX15/2503 suppressed tumor growth in syngeneic and transgenic tumors. No toxicologic effects were noted in studies of VX15/2503 using rats and primates and PK/PD profiles were generally predictive of data from clinical trial subjects. Methods: A multiple ascending dose trial was initiated in adult pts with advanced refractory solid tumors; pts were administered weekly IV doses of VX15/2503 until progression. Dose levels were 0.3 to 20 mg/kg. Tumors were assessed by RECIST 1.1 after each 8 dose cycle. Biomarkers assessed were SEMA4D, VEGF, HGF, PLGF, and MET. Results: Enrollment has been concluded (n=42 Pts); sex 40.5%M/59.5%F. Mean age (yrs) 64.8; ECOG 0/1/2 are 28.6% /69%/4%. No MTD was found. One DLT (grade 3 GGT elevation; 15 mg/kg) was reported in a pancreatic cancer pt with disease progression. As of 12/16/2013 the most frequent treatment-related AE’s (n=42 pts) included grade 1/2 nausea (11.7%), arthralgia (7.3%), decreased appetite (7.3%), and fatigue (7.3%); 15 drug unrelated SAE’s were reported in 11 pts. No CR/PR were observed. Thirteen of 42 pts at all dose levels exhibited stable disease for at least 8 weeks. Pts with the longest duration of treatment included: 48-55 weeks (colorectal; 9 mg/kg) (breast; 15 mg/kg) (papillary thyroid; 20 mg/kg); these pts had relatively high T or B cell levels. VX15/2503 serum concentrations of ≥ 0.3 µg/mL produced complete T cell SEMA4D saturation. HAHA responses (titer > 100) with possible effects on PK were observed in 4 of 41 pts (10%); in only 1 pt (2%) was an effect of HAHA on PD observed. VX15/2503 half-life was roughly 4-5 days at doses ≥1.0 mg/kg. Conclusions: VX15/2503 was well tolerated at dose levels up to 20 mg/kg, with 450 doses administered to 42 pts. Future studies will be combination trials in selected tumor types. Clinical trial information: NCT01313065.